Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out ...

The top-line growth was primarily driven by higher royalty payments from Roche RHHBY for Phesgo and J&J JNJ for subcutaneous Darzalex (daratumumab) as well as an increase in milestone revenues ...

Halozyme now has several marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s JNJ Darzalex and Roche’s Phesgo. The company’s top line comprises ...

This continued strong growth will be primarily driven by three products: DARZALEX subcutaneous, Phesgo and VYVGART Hytrulo. Let me begin with DARZALEX on Slide 5. For the fourth quarter of 2024 ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.26, expectations were $1.17 ...

Halozyme now has several marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s Darzalex and Roche’s Phesgo. Shares of Halozyme were up 1.9% in ...

Our 2024 royalty revenue exceeded guidance driven by continued strong growth of DARZALEX SC and Phesgo, with modest initial contribution from VYVGART Hytrulo resulting from growing adoption and ...

Key drivers are DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo. CFO Nicole LaBrosse emphasized strong Q4 financial results, including a 30% increase in revenue to $298 million and a 61% rise ...